BioSpace News Archive

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today provided an update on MARIO-275, the Company’s randomized, placebo controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced, metastatic urothelial cancer (mUC) over nivolumab monotherapy which is approved in this setting.

Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors for the purchase and sale of 32,630,983 of its shares of common stock at a purchase price of $1.10 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about January 8, 2021, subject to the satisfaction of customary c

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will participate in the following two upcoming virtual investor conferences. Conference: H.C. Wainwright BioConnect Conference

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced Holy Name Medical Center in Teaneck, New Jersey has acquired a Sensus low-dose radiation therapy system for the treatment of pneumonia in COVID-19 patients.

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that, based on its preliminary internal financial reporting for the fourth quarter 2020, unaudited quarterly revenue is anticipated to be the highest in the Company’s history and to surpass analyst estimates.

-CAHmelia Adult Classic CAH Program Underway in U.S. and Europe- -Initiation of Phase 2 Pediatric Classic CAH Program Anticipated in Second Half of 2021- -Initiation of Phase 2 Polycystic Ovary Syndrome Program Anticipated in Second Half of 2021- -New Patent Issuance Extends Tildacerfont Patent Exclusivity through 2038-

Spectrum Solutions, LLC today announced receiving CE Mark approval for the sale and distribution of its groundbreaking SDNA saliva collection device for IVD molecular diagnostic testing throughout Europe.

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021. Details of the events are as follows: 10 th Annual LifeSci Partners Corporate Access Event: The company will host virtual one-on-one meetings during the conference on Wednesday,

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will participate in the following virtual investor conferences during January 2021. H.C. Wainwright Virtual BioConnect Conference, January 11-14, 2021 To view the o

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.: 39th Annual J.P. Morgan Healthcare Conference Wednesday, January 13 at 11:40 a.m. Eastern Time H.C. Wainwright Virtual BioConnect Conference On-demand presentation a